JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 131 filers reported holding JOUNCE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 5.36 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $169,000 | -44.4% | 24,900 | -31.6% | 0.00% | -100.0% |
| Q4 2021 | $304,000 | +7.8% | 36,400 | -4.2% | 0.00% | 0.0% |
| Q3 2021 | $282,000 | +12.8% | 38,000 | +3.5% | 0.00% | 0.0% |
| Q2 2021 | $250,000 | -53.5% | 36,700 | -30.0% | 0.00% | 0.0% |
| Q1 2021 | $538,000 | +10.0% | 52,400 | -25.0% | 0.00% | 0.0% |
| Q4 2020 | $489,000 | +48.2% | 69,900 | +73.0% | 0.00% | 0.0% |
| Q3 2020 | $330,000 | +226.7% | 40,400 | +174.8% | 0.00% | – |
| Q2 2020 | $101,000 | -5.6% | 14,700 | -35.0% | 0.00% | – |
| Q1 2020 | $107,000 | 0.0% | 22,600 | +4.6% | 0.00% | – |
| Q2 2019 | $107,000 | -18.3% | 21,600 | +2.4% | 0.00% | – |
| Q1 2019 | $131,000 | +138.2% | 21,100 | +29.4% | 0.00% | – |
| Q4 2018 | $55,000 | – | 16,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 572,829 | $1,340,000 | 100.00% |
| TRV GP III, LLC | 1,148,780 | $2,688,000 | 1.17% |
| COWEN AND COMPANY, LLC | 3,647,430 | $8,535,000 | 0.82% |
| Octagon Capital Advisors LP | 1,400,000 | $3,276,000 | 0.56% |
| Deep Track Capital, LP | 4,259,653 | $9,968,000 | 0.46% |
| PFM Health Sciences, LP | 4,094,488 | $9,581,000 | 0.35% |
| RTW INVESTMENTS, LP | 5,106,341 | $11,949,000 | 0.28% |
| Omega Fund Management, LLC | 275,513 | $645,000 | 0.24% |
| Monarch Partners Asset Management LLC | 228,370 | $534,000 | 0.16% |
| Orbimed Advisors | 2,928,900 | $6,854,000 | 0.13% |